SBRT has excellent outcomes for intermediate-risk patients

Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …

Whole pelvic salvage radiation + short-term ADT improves oncologic outcomes

We didn’t expect to see data from the SPPORT trial for another 2 years, but the research team hit their recruitment goal early and have already been able to provide 5-year results. … READ MORE …

New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

Effects of prazosin + radiation therapy on recurrence-free survival

The following was brought to our attention by Arthur as a consequence of a question posed on Ask Arthur by a reader within the past 24 hours. … READ MORE …

ASTRO, ASCO, and AUA strongly endorse shortened course of IMRT for primary therapy

It will come as no surprise to our readers that moderately hypofractionated IMRT (first-line radiation delivered in 20 to 26 treatments or fractions instead of the conventional 40-44 fractions) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. … READ MORE …

I-131-MIP-1095 to enter randomized, Phase II clinical trial

As we reported last year, a new radiopharmaceutical has entered the pack. … READ MORE …

No survival benefit to debulking the prostate with radiation in first randomized clinical trial

The term “debulking” denotes the radical treatment (via prostatectomy or radiation therapy) of the cancerous prostate — lmost always in newly diagnosed patients — after distant metastases have been discovered. … READ MORE …